Patents Represented by Attorney, Agent or Law Firm Karen B. King
  • Patent number: 8084481
    Abstract: The present application relates to novel, substituted 4-arylimidazol-2-ones and 5-aryl-1,2,4-triazolones, processes for the production thereof, the use thereof alone or in combinations for the treatment and/or prevention of diseases and the use thereof for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.
    Type: Grant
    Filed: May 21, 2007
    Date of Patent: December 27, 2011
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Heinrich Meier, Eckhard Bender, Ulf Brüggemeier, Ingo Flamme, Dagmar Karthaus, Peter Kolkhof, Daniel Meibom, Dirk Schneider, Verena Voehringer, Chantal Fürstner, Jörg Keldenich, Dieter Lang, Elisabeth Pook, Carsten Schmeck
  • Patent number: 8058447
    Abstract: The present application relates to novel 4-chromenonyl-1,4-dihydropyridinecarbonitriles, processes for their preparation, pharmaceutical compositions containing them, and their use for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders.
    Type: Grant
    Filed: July 14, 2006
    Date of Patent: November 15, 2011
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Alexander Kuhl, Peter Kolkhof, Heike Heckroth, Karl-Heinz Schlemmer, Ingo Flamme, Santiago Figueroa Perez, Heike Gielen-Haertwig, Rolf Grosser, Jens-Kerim Ergüden, Dieter Lang
  • Patent number: 7998988
    Abstract: The invention relates to biphenyl compounds of formula (I): wherein U, V and W together form a group of the formula *—CH?CH—CH<, *—CH2—CH2—CH< or *—CH2—CH2—N<, in which * means the point of linkage to the phenyl ring; A is O or CH2; and D, E, X, Y, Z, R1, R2, o, n, and p are as defined in the specification. The invention also relates to pharmaceutical compositions of the compound of the compounds. The compounds and pharmaceutical compositions of the invention can be used in the treatment or prevention of cardiovascular disorders.
    Type: Grant
    Filed: October 9, 2006
    Date of Patent: August 16, 2011
    Assignee: Bayer Schering Pharma Aktiengellschaft
    Inventors: Stephan Bartel, Michael Hahn, Wahed Ahmed Moradi, Klaus Münter, Thomas Rölle, Johannes-Peter Stasch, Karl-Heinz Schlemmer, Frank Wunder
  • Patent number: 7985876
    Abstract: The invention relates to novel substituted dibenzoic acid derivatives of formula (I), wherein A represents a group of formula (II) or (III), to methods for producing the same, and to their use in the treatment and/or prophylaxis of diseases. The invention also relates to the use of said substances in the production of drugs for the treatment and/or prophylaxis of diseases, especially in the treatment and/or prevention of cardiovascular diseases.
    Type: Grant
    Filed: March 15, 2008
    Date of Patent: July 26, 2011
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Michael Hahn, Eva-Maria Becker, Andreas Knorr, Dirk Schneider, Johannes-Peter Stasch, Karl-Heinz Schlemmer, Frank Wunder, Dieter Lang
  • Patent number: 7906016
    Abstract: A system includes a first source including a first reactant; a second source including a second reactant capable of reacting with the first reactant to form a first product; and a reactor. The reactor includes a first element having a wall connecting a first point and a second point, the wall extending more than 180° around the first point; and a second element movably engaged with the first element to define a reconfigurable reaction chamber capable of being in fluid communication with the first and second reactants.
    Type: Grant
    Filed: August 20, 2008
    Date of Patent: March 15, 2011
    Assignee: TIAX LLC
    Inventors: Robert S. Weber, Mark Marion, Jayanti Sinha, William Barney
  • Patent number: 7861541
    Abstract: In a refrigeration system, an asymmetric scroll expander has an orbiting scroll element engaged with a fixed scroll element. The orbiting scroll element and fixed scroll element can define a first expansion pocket and a second expansion pocket at positions relative to one another.
    Type: Grant
    Filed: July 13, 2005
    Date of Patent: January 4, 2011
    Assignee: Tiax LLC
    Inventors: John T. Dieckmann, Detlef Westphalen
  • Patent number: 7857616
    Abstract: A burner apparatus utilizes a reticulated member to promote mixing of a fuel and oxidizer mixture. A plurality of exit ports, disposed on a wall or surface encapsulating the reticulated member, defines exit streams of the mixture that produces flames upon combustion. The burner apparatus have high heating rates and turndown ratios of at least about 18:1.
    Type: Grant
    Filed: April 6, 2005
    Date of Patent: December 28, 2010
    Assignee: TIAX LLC
    Inventors: Philip C. Carbone, Matthew E. Brekken, Peter F. Pescatore, Charles E. Marble, Matthew Rhodes
  • Patent number: 7029465
    Abstract: The present invention presents a novel ampoule filtration system, and novel methods and devices for using the system to deliver multi-doses of a sterile solution of a therapeutic agent to a subject. The ampoule filtration system includes a sterile filter cartridge attached to the mouth of an ampoule, such that liquid dispensed from the ampoule is drawn through the cartridge, and a means for sealingly engaging the filtration system to a delivery device.
    Type: Grant
    Filed: April 10, 2003
    Date of Patent: April 18, 2006
    Assignee: Pharmacia Corporation
    Inventors: Robert H. Heyes, Peter N. Carpenter, Remo Ponta
  • Patent number: 6696426
    Abstract: There is provided a pharmaceutical preservative free composition suitable for topical administration to an eye, the composition comprising (a) an oxazolidinone antimicrobial drug, for example linezolid, in a therapeutically or prophylactically effective drug concentration that is above the practical limit of solubility of the drug in a substantially isotonic aqueous solution at a physiologically compatible pH, and (b) a pharmaceutically acceptable cyclodextrin compound in a concentration sufficient to maintain the drug in solution at such a drug concentration. The composition is particularly useful for the treatment and/or prevention of eye infections due to gram positive bacteria.
    Type: Grant
    Filed: February 22, 2002
    Date of Patent: February 24, 2004
    Assignee: Pharmacia Corporation
    Inventors: Satish K. Singh, Lisa A. Adams, Paramita Bandyopadhyay, Syed Hasan, Leslie C. Hawley, Sandra M. Sims
  • Patent number: 6551584
    Abstract: There is provided a pharmaceutical composition suitable for topical administration to an eye, the composition comprising as active agent at least one oxazolidinone antibacterial drug, for example linezolid, in a concentration effective for treatment and/or prophylaxis of a gram-positive bacterial infection of an eye, and at least one ophthalmically acceptable excipient ingredient that reduces a rate of removal of the composition from the eye by lacrimation such that the composition has an effective residence time in the eye of about 2 to about 24 hours. The composition is, for example, an in situ gellable solution, suspension or solution/suspension.
    Type: Grant
    Filed: October 10, 2001
    Date of Patent: April 22, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Rebanta Bandyopadhyay, Pamela J. Secreast, Leslie C. Hawley, Vincent E. McCurdy, Praveen Tyle, Paramita Bandyopadhyay, Satish Kumar Singh
  • Patent number: 6495157
    Abstract: A highly storage-stable composition for vaginal administration of clindamycin is disclosed which is useful for the treatment of bacterial vaginosis. The composition is a vaginal suppository containing an antimicrobially effective amount of clindamycin dispersed in a Hard Fat NF suppository base. Hard Fat NF suppository bases provide a clindamycin product having long term storage stability while providing efficacy against bacterial vaginosis which is equivalent to clindamycin vaginal creams.
    Type: Grant
    Filed: July 20, 2000
    Date of Patent: December 17, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventors: Lorraine Elisabeth Pena, Phil Bryan Bowman, Robert Shih-Liang Chao, Carolyn V. Pesheck
  • Patent number: 6479235
    Abstract: Methods and materials are disclosed for use in simultaneously amplifying at least thirteen loci of genomic DNA in a single multiplex reaction, as are methods and materials for use in the analysis of the products of such reactions. Included in the present invention are materials and methods for the simultaneous amplification of at least thirteen short tandem repeat loci, including specific materials and methods for the analysis of thirteen such loci specifically selected by the United States Federal Bureau of Investigation as core loci for use in the Combined DNA Index System (CODIS) database.
    Type: Grant
    Filed: November 25, 1998
    Date of Patent: November 12, 2002
    Assignee: Promega Corporation
    Inventors: James W. Schumm, Cynthia J. Sprecher
  • Patent number: 6402887
    Abstract: A method using biological processes in the production of pulp from industrial wood waste is described. The process makes use of various species of white-rot fungi which selectively degrade lignin. The industrial wood waste must be cleaned and hydrated prior to inoculation with the fungus. Paper produced by this process has excellent strength characteristics as compared to both non-treated industrial wood waste and pulp produced from virgin wood chips. Substantial energy savings are also realized when the biopulped industrial wood waste chips are further refined by conventional mechanical pulping procedures. Kraft pulping of wood waste resulted in strength properties comparable to those of virgin wood. Fungal pretreatment subsequently enhanced the resulting kraft pulp properties.
    Type: Grant
    Filed: November 30, 1998
    Date of Patent: June 11, 2002
    Assignees: Biopulping International, Inc., The United States of America as represented by the Secretary of Agriculture
    Inventors: Masood Akhtar, Gary M. Scott, Aziz Ahmed, Michael J. Lentz, Eric G. Horn
  • Patent number: 6365172
    Abstract: This invention relates to fiber-forming bioabsorbable poly(ester-amide)s made by the polymerization of diamidediols with 3,6-dioxaoctanedioic acid, also known as “triglycolic acid”. More specifically it relates to diol terminated poly(ester-amide)s of triglycolic acid that are optionally further reacted with glycolide, lactide, trimethylene carbonate, epsilon-caprolactone, or p-dioxanone, or mixtures of said cyclic monomers to produce the corresponding block copolymers. Said polymers are useful in the production of surgical sutures having superior performance characteristics including low bending stiffness and in the production of other fiber-based bioabsorbable implants and molded devices.
    Type: Grant
    Filed: August 1, 2000
    Date of Patent: April 2, 2002
    Assignee: BioAmide, Inc.
    Inventor: Thomas Harry Barrows
  • Patent number: 6350452
    Abstract: Disclosed are antibodies that specifically recognize the new amino terminus of a protein cleaved by a protease during apoptosis. Methods of using and making the antibodies are also provided. The antibodies are particularly useful in methods of detecting apoptosis and testing candidate compounds for enhancing or inhibiting apoptosis.
    Type: Grant
    Filed: December 8, 1999
    Date of Patent: February 26, 2002
    Assignee: Promega Corporation
    Inventor: Terry Riss
  • Patent number: 6310199
    Abstract: pH dependent ion exchange matrices are provided, with methods for making such matrices, and methods for using such matrices to isolate a target nucleic acid, such as plasmid DNA, chromosomal DNA, or RNA from contaminants, including proteins, lipids, cellular debris, or other nucleic acids. Each pH dependent ion exchange matrix of this invention comprises at least two different ion exchange functional groups, one of which is capable of acting as an anion exchanger at a first pH, and the other of which is capable of acting as a cation exchanger at a second, higher pH. The matrix has an overall neutral charge in a pH range between the first and second pH. The pH dependent ion exchange matrices of the present invention are designed to bind to the target nucleic acid at a pH wherein the overall charge of the matrix is positive, and to release the target nucleic acid as the pH of the surrounding solution is increased.
    Type: Grant
    Filed: May 14, 1999
    Date of Patent: October 30, 2001
    Assignee: Promega Corporation
    Inventors: Craig E. Smith, Diana L. Holmes, Daniel J. Simpson, Jehoshua Katzenhendler, Rex M. Bitner, Josephine C. Grosch
  • Patent number: 6284470
    Abstract: Methods are disclosed for using paramagnetic particles to concentrate or harvest cells. Methods are also disclosed for clearing a solution of disrupted biological material, such as a lysate of cells or a homogenate of mammalian tissue. Methods are also disclosed for using paramagnetic particles to isolate target nucleic acids, such as RNA or DNA, from a solution cleared of disrupted biological material using the same type or a different type of paramagnetic particle. Kits are also disclosed for use with the various methods of the present invention. Nucleic acids isolated according to the present methods and using the present kits are suitable for immediate use in downstream processing, without further purification.
    Type: Grant
    Filed: August 24, 2000
    Date of Patent: September 4, 2001
    Assignee: Promega Corporation
    Inventors: Rex M. Bitner, Craig E. Smith, Douglas H. White, Braeden L. Butler, Jacqui Sankbeil
  • Patent number: 6270970
    Abstract: Mixed-bed solid phases are provided, with methods for using such solid phases to isolate target nucleic acids, such as plasmid DNA, chromosomal DNA, RNA, or nucleic acids generated by enzymatic amplification from contaminants, including proteins, lipids, cellular debris, or other nucleic acids. The mixed-bed solid phases of this invention are mixtures of at least two different solid phases, each of which has a capacity to bind to the target nucleic acid under different solution conditions, and the capacity to release the nucleic acid under similar elution conditions. By exchanging solution conditions according to the methods of this invention, one can remove contaminants from the target nucleic acid bound to the mixed-bed solid phase, then elute the target nucleic acid in an elution buffer.
    Type: Grant
    Filed: May 14, 1999
    Date of Patent: August 7, 2001
    Assignee: Promega Corporation
    Inventors: Craig E. Smith, Diana L. Holmes, Daniel J. Simpson, Jehoshua Katzenhendler, Rex M. Bitner, Josephine C. Grosch
  • Patent number: 6238863
    Abstract: The present invention is directed to materials and methods for the identification and analysis of intermediate tandem repeat sequences in DNA, wherein an intermediate tandem repeat (ITR) sequence is a region of a DNA sequence containing at least one five to seven base repeat unit appearing in tandem at least two times. DNA markers to highly polymorphic ITR loci in the human genome are identified and analyzed, using particularly preferred embodiments of the materials and methods of the present invention.
    Type: Grant
    Filed: February 4, 1998
    Date of Patent: May 29, 2001
    Assignee: Promega Corporation
    Inventors: James W. Schumm, Jeffery W. Bacher
  • Patent number: 6221598
    Abstract: The present invention is directed to the simultaneous amplification of multiple distinct genetic loci using PCR or other amplification systems to determine in one reaction the alleles of each locus contained within the multiplex.
    Type: Grant
    Filed: June 7, 1999
    Date of Patent: April 24, 2001
    Assignee: Promega Corporation
    Inventors: James W. Schumm, Cynthia J. Sprecher, Ann M. Lins